Central Nervous System-Antipsychotics
= Additional active ingredients
PRESENTATION AND DOSSAGE
TABS: 28 X 10 mg
TABS: 28 X 5 mg
Acute monotherapy: Treatment of acute mixed or manic episodes associated with Bipolar I Disorder. Preventing recurrence in bipolar disorder: In patients whose manic episodes have responded to olanzapine treatment, therapy is indicated for the prevention of recurrence in patients with Bipolar Disorder.
Known hypersensitivity to the product.
Neuroleptic malignant syndrome has been reported in association with administration of antipsychotic drugs, including olanzapine. Tardive dyskinesia, potentially irreversible, may develop in patients treated with antipsychotic drugs. Should be prescribed in a manner that is most likely to minimize the occurence of tardive dyskinesia. May induce orthostatic hypotension. Patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension. Should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold. As with other drugs that antagonize dopamine D2 receptors, olanzapine elevates prolactin levels, and a modest elevation persists during chronic administration. The possibility of suicide attempt is inherent in schizophrenia and in bipolar disorder, and close supervision of high-risk patients should accompany drug therapy.
Schizophrenia: Postular hypotension, constipation, weight gain, dizziness, personality disorder, akathisia. Bipolar mania: Asthenia, dry mouth, constipation, dyspepsia, increased appetite, somnolence, dizziness, tremor.
Alcohol, CNS depressants, cimetidine, disulfiram, carbamazepine, levodopa.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Eli Lilly Israel Ltd.
License Holder: Eli Lilly Israel Ltd.